TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15521004
Drug: BILN 2061
Approvals — FDA: no, EMA: no, PMDA: no
Description: BILN 2061 500 mg twice daily for 2 days
Study: 15521004
Drug: BILN 2061
Approvals — FDA: no, EMA: no, PMDA: no
Description: BILN 2061 200 mg twice daily for 2 days
Study: 15521004
Drug: BILN 2061
Approvals — FDA: no, EMA: no, PMDA: no
Description: BILN 2061 25 mg twice daily for 2 days
Study: 11161394
Drug: Amifostine (910
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amifostine (910 mg/m² at day 1-3)
Study: 9788689
Drug: Budesonide (topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (topical steroid treatment)
Study: 9788689
Drug: Levocabastine (topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocabastine (topical antihistamine)
Study: 9788689
Drug: Polyclonal antibody
Normalized name: Polyclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyclonal antibody against SCF
Study: 2791180
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg IV prochlorperazine
Study: 321183
Drug: aspirin 3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: aspirin 3.6 g daily
Study: 31900997
Drug: Inhaled verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled verapamil (10 mg)
Study: 31900997
Drug: Control (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (4 cc nebulized distilled water)
Study: 29057836
Drug: Citrulline Malate
Normalized name: CITRULLINE MALATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citrulline Malate (CM) 6 g
Study: 26150574
Drug: Blood volume
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood volume expansion with albumin solution in 38°C (T38A)
Study: 21726984
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection of 1g every 8 h (q8h) for 24 h
Study: 21726984
Drug: 3‐h infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3‐h infusion of 1 g q8h for 24 h
Study: 21726984
Drug: 3‐h infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3‐h infusion of 2 g q8h for 24 h
Study: 19292653
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (plain adhesive patch)
Study: 12680181
Drug: Cyclophosphamide 500
Normalized name: cyclophosphamide 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide 500 mg/m2 on days 1 and 2 plus epidoxorubicin 90 mg/m2 on day 1 every 3 weeks (group A)
Study: 12680181
Drug: Paclitaxel 175
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 175 mg/m2/cycle plus doxorubicin 50 mg/m2/cycle every 3 weeks (group B)
Study: 12680181
Drug: Paclitaxel 175
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 175 mg/m2/cycle plus epidoxorubicin 90 mg/m2/cycle every 21 days (group C)
Study: 4054064
Drug: Intracervical application
Normalized name: eladocagene exuparvovec
DrugBank: Eladocagene exuparvovec (DB16780)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracervical application of 0.1 mg Sulprostone‐Tylose gel
Study: 4054064
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment with local prostaglandin)
Study: 30076108
Drug: High-dose-rate brachytherapy
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose-rate brachytherapy boost with 23 fractions of IMRT and 2 fractions of brachytherapy
Study: 30076108
Drug: Intensity-modulated radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensity-modulated radiation therapy (IMRT) alone with 44 fractions
Study: 22552183
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (pharmacological therapy)
Study: 12641687
Drug: Bupivacaine 0.125%
Normalized name: BUPIVACAINE 0.125%/NS INJ 250ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.125% 1 ml.kg(‐1) (group B, n = 15)
Study: 12641687
Drug: Bupivacaine 0.125%
Normalized name: BUPIVACAINE 0.125%/NS INJ 250ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.125% 1 ml.kg(‐1) and preservative‐free s‐ketamine 0.5 mg.kg(‐1) (group K, n = 15)
Study: 10682152
Drug: Zidovudine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine (200 mg three times daily) plus Lamivudine (300 mg twice daily)
Study: 10682152
Drug: Zidovudine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine (200 mg three times daily) plus Lamivudine (300 mg twice daily) plus Loviride (100 mg three times daily)
Study: 8917255
Drug: Reviparin (7,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reviparin (7,000 U bolus before PTCA, followed by 10,500 U infusion over 24 h, then 3,500 U subcutaneous application twice daily for 28 days)
Study: 8917255
Drug: Control (10,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (10,000 U unfractionated heparin bolus followed by 24,000 U infusion over 24 h, then subcutaneous placebo injections for 28 days)
Study: 1888046
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine sulfate (ITMS) 15 micrograms.kg‐1
Study: 1888046
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine sulfate (ITMS)
Study: 6802018
Drug: Combined intravenous
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined intravenous administration of 18 mg/h dihydralazine and 0.6 mg/h nitroglycerin
Study: 29860524
Drug: brief cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: brief cognitive behavioral therapy (bCBT)
Study: 30236042
Drug: Topical sinecatechins
Normalized name: sinecatechins Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical sinecatechins (TS) 10% applied twice daily after CO2 laser treatment; 60 subjects in this group.
Study: 30236042
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment); 27 subjects in this group.
Study: 30236042
Drug: Topical sinecatechins
Normalized name: sinecatechins Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical sinecatechins (TS) 10% applied twice daily; 60 subjects in this group.
Study: 24342522
Drug: lanreotide, 120
Normalized name: Lanreotide, 120 mg/0.5 mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: lanreotide, 120 mg, subcutaneously every 28 days for 120 weeks
Study: 22035883
Drug: Double-dose methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Double-dose methotrexate (50mg/m² intramuscularly on days 0 and 4)
Study: 22035883
Drug: Single-dose methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single-dose methotrexate (50mg/m² intramuscularly on day 0)
Study: 22035883
Drug: Double-dose methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Double-dose methotrexate
Study: 9091325
Drug: Single-dose methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single-dose methotrexate
Study: 20538165
Drug: HDL selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDL selective delipidated plasma infusions
Study: 18834244
Drug: SRP plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP plus adjunctive MOX
Study: 18834244
Drug: SRP plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP plus adjunctive DOX
Study: 24714829
Drug: Glutamine treatment
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine treatment
Study: 15983685
Drug: No glutamine
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No glutamine treatment (Control)
Study: 11792919
Drug: Lidocaine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (5 ml of 1% lidocaine)
Study: 11792919
Drug: Control (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (5 ml of 0.9% sodium chloride)
Study: 1897808
Drug: Bricanyl Turbuhaler
Normalized name: terbutaline sulfate Oral Solution [Bricanyl]
DrugBank: Terbutaline (DB00871)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bricanyl Turbuhaler (0.5 mg x 1 terbutaline)
Study: 1897808
Drug: Albuterol metered
Normalized name: albuterol Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol metered dose inhaler (0.1 mg x 2 albuterol)
Study: 27405587
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for Anxiety Treatment in Schools (CATS)
Study: 25370953
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of acotiamide
Study: 25370953
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of acotiamide
Study: 11881883
Drug: More soluble
Normalized name: Sore No More
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: More soluble agents (Isoflurane, enflurane)
Study: 10207805
Drug: Diuretics plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics plus albumin, 12.5 g/day (group B)
Study: 10207805
Drug: Diuretics plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics plus albumin (25 g/week) (group B)
Study: 10207805
Drug: Diuretics (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics (group A)
Study: 2650896
Drug: Group I:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group I: 20 ml of lidocaine two per cent with epinephrine via needle at a rate of 5 ml.30 sec‐1 after a 3 ml test dose
Study: 2650896
Drug: Group II:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group II: 20 ml of lidocaine two per cent with epinephrine in increments of 5 ml injected through a catheter after a 3 ml test dose
Study: 971703
Drug: Cefoxitin (0.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin (0.5, 1, and 2 g)
Study: 971703
Drug: Cephalothin (0.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalothin (0.5, 1, and 2 g)
Study: 31543474
Drug: Sertraline 50
Normalized name: sertraline 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 50 mg daily for one week, then 100 mg daily for up to 11 weeks
Study: 26031901
Drug: Zileuton treatment
Normalized name: Zileuton
DrugBank: Zileuton (DB00744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zileuton treatment
Study: 24908956
Drug: Vazonat (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vazonat (1000 mg/day intravenously for 15 days, then 250 mg 3 times per os for 1 month)
Study: 24908956
Drug: Vazonat (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vazonat (1000 mg/day intravenously for 15 days, then 250 mg 3 times per os for 1 month) + Adapto (500 mg twice a day throughout the supervision period)
Study: 20217115
Drug: Glucose ingestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose ingestion (75 g of glucose 1 hour before exercise)
Study: 10902827
Drug: Enoxaparin sodium
Normalized name: Enoxaparin Sodium
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enoxaparin sodium (40 mg daily)
Study: 8737216
Drug: L-propionylcarnitine (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-propionylcarnitine (1500 mg daily for 6 weeks)
Study: 8737216
Drug: Diltiazem (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (180 mg daily for 3 weeks, followed by 360 mg daily for 3 weeks)
Study: 7840730
Drug: metoprolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoprolol (100 mg/day)
Study: 7840730
Drug: nicardipine (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: nicardipine (90 mg/day)
Study: 7840730
Drug: captopril (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: captopril (75 mg/day)
Study: 31161855
Drug: Isostretching twice
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isostretching twice a week for 45 days
Study: 31161855
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (waiting list for physical therapy)
Study: 31596326
Drug: Full-mouth scaling
Normalized name: moth bean extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-mouth scaling (FMS) with systemic azithromycin (500 mg/day for three consecutive days)
Study: 31596326
Drug: Quadrant-wise scaling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrant-wise scaling and root planning (QSRP) with systemic azithromycin (500 mg/day for three consecutive days)
Study: 28719693
Drug: 2000 IU/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 IU/d of vitamin D oral supplementation (high-dose group)
Study: 28719693
Drug: 400 IU/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 IU/d of vitamin D oral supplementation (standard-dose group)
Study: 8780279
Drug: Patient-controlled intranasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled intranasal analgesia (PCINA)
Study: 27082959
Drug: Intravenous patient-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous patient-controlled analgesia (IV PCA)
Study: 1502842
Drug: Trivalent influenza
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent influenza virus vaccine containing B/Yamagata/16/88
Study: 9087158
Drug: Clemastine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clemastine (0.5 mg)
Study: 6429878
Drug: Sodium Cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium Cromoglycate (20 mg)
Study: 6429878
Drug: Ketotifen (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen (0.5 mg)
Study: 31299392
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) using 5% 5-aminolevulinic acid in gel form, irradiated with a halogen lamp (590-760 nm) for 10 minutes, repeated weekly for 10 weeks.
Study: 27013028
Drug: Standard Multimodal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Multimodal Therapy (TRAD)
Study: 25809913
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with probiotics (Bacillus subtilis and Streptococcus faecium) and mosapride (various doses)
Study: 25809913
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with probiotics and mosapride
Study: 25809913
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with probiotics and mosapride (group 4)
Study: 25809913
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with probiotics (group 1)
Study: 25809913
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with probiotics (group 4)
Study: 23599248
Drug: Intermittent infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent infusion (every 4 hours from 8:00 to 20:00)
Study: 23599248
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion (24 hours/d)
Study: 22581391
Drug: THC (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC (400 μg/kg body weight) with alcohol
Study: 22581391
Drug: Alcohol (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (doses aimed at 0.5 and 0.7 mg/mL) with THC
Study: 22581391
Drug: Dräger Drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dräger Drug Test® 5000
Study: 12554916
Drug: Prolonged antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged antibiotic therapy
Study: 17695680
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of prolonged antibiotic therapy and surgery
Study: 9739379
Drug: Hyperfractionated radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperfractionated radiotherapy (1.2 Gy bid, total dose 74.4 Gy) and simultaneous CDDP chemotherapy (20 mg/m2 daily, 5 days in week 1 and 5)
Study: 9739379
Drug: Hyperfractionated radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperfractionated radiotherapy and simultaneous CDDP chemotherapy
Study: 9425393
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of SS20 infusion
Study: 2523322
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg NET injectable microspheres
Study: 2523322
Drug: 65 mg
Normalized name: opium 65 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 65 mg NET injectable microspheres
Study: 2523322
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses (65 mg and 100 mg)
Study: 19596188
Drug: Ciclesonide 160
Normalized name: CICLESONIDE 160MCG 60D ORAL INHL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclesonide 160 microg once daily via metered-dose inhaler (CIC160)
Study: 19596188
Drug: Ciclesonide 160
Normalized name: CICLESONIDE 160MCG 60D ORAL INHL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclesonide 160 microg once daily via AeroChamber Plus (CIC160P)
Study: 19596188
Drug: Ciclesonide 160
Normalized name: CICLESONIDE 160MCG 60D ORAL INHL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclesonide 160 microg once daily via AeroChamber MAX (CIC160M)
Study: 15039411
Drug: Expanded medical
Normalized name: Allogeneic, ex-vivo expanded, umbilical cord blood-derived hematopoietic CD34+ progenitor cells - cultured fraction (CF)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expanded medical treatment
Study: 15080829
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with Dermatophagoides pteronyssinus and D. farinae 50/50 allergen extract for 2 years
Study: 3108045
Drug: Combination clomiphene/hMG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination clomiphene/hMG
Study: 26604272
Drug: Systemic amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic amoxicillin and metronidazole during the first, nonsurgical phase of periodontal therapy (phase 1)
Study: 26604272
Drug: Adjunctive antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive antibiotics during the first phase
Study: 26604272
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving antibiotics during the second, surgical phase (phase 2)
Study: 26604272
Drug: Adjunctive antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive antibiotics during the second phase
Study: 22454003
Drug: Flexible(MIB) regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexible(MIB) regimen (24-120 days' active hormonal intake with 4-day tablet-free intervals)
Study: 22454003
Drug: Conventional regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional regimen (24 days' active hormonal intake followed by a 4-day hormone-free interval)
Study: 22454003
Drug: Fixed extended
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed extended regimen (120 days' uninterrupted active hormonal intake followed by a 4-day tablet-free interval)
Study: 15672015
Drug: Glyburide (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide (low dose ≤10 mg)
Study: 15672015
Drug: Glyburide (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide (high dose >10 mg)
Study: 7926425
Drug: Glyburide and
Normalized name: Glyburide and metformin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide and Insulin
Study: 10863393
Drug: Periodontal instrumentation
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Periodontal instrumentation plus TTC‐HCl plus trypsin solution after extraction (test 2)
Study: 10863393
Drug: Periodontal instrumentation
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Periodontal instrumentation plus trypsin solution after extraction (control 2)
Study: 7499781
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid 600 mg per day for 2 months
Study: 7250177
Drug: Oral metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral metoclopramide (10 mg)
Study: 28459163
Drug: Mirror therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirror therapy + neuromuscular electrical stimulation
Study: 21615299
Drug: 5% albumin
Normalized name: Flexbumin 5% Albumin (Human) Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% albumin solution (albumin-bolus group)
Study: 21615299
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline solution (saline-bolus group)
Study: 19408724
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide (40 mg/ml)
Study: 19408724
Drug: IFN alpha‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN alpha‐2b (15 x 10(5) U/ml)
Study: 26911400
Drug: Verapamil (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (2.5 mg/ml)
Study: 17218799
Drug: Gabapentin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (600 mg/day)
Study: 17218799
Drug: Gabapentin (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (1200 mg/day)
Study: 17218799
Drug: Gabapentin (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (0 mg/day)
Study: 17218799
Drug: Cocaine doses
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine doses (0, 12, 25, 50 mg)
Study: 342318
Drug: Vaccine with
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine with 6 log EID50/dose